Healthcare models in other high-income countries such as
Norway may be key to improving NZ’s ovarian cancer
survival rates and require more investigation, according to
the head of gynaecological cancer foundation Talk
Peach.
The call to learn from the success
of other international healthcare models comes as Te Whatu
Ora – Health New Zealand and Te Aho o Te Kahu – the Cancer
Control Agency, prepare to establish the new Cancer National
Clinical Network – designed to improve health outcomes and
reduce variations in access to cancer care in
NZ.[1]
The new network, which is set to
have its first meeting early this year, aims to tackle
critical challenges in cancer care, including expanding
workforce capacity to meet rising demand, creating
sustainable and equitable care models and addressing
disparities in access and outcomes.[2][3]
Māori,
Pacific peoples, disabled individuals, and those living in
poverty are disproportionately affected, facing higher rates
of cancer diagnoses and poorer outcomes. The initiative will
focus on reducing variations in care to ensure more
coordinated and effective cancer treatment across the health
system.[4]
Tash Crosby, cancer survivor and founder of
Talk Peach Gynaecological Cancer Foundation says the success
of oncology treatment models in parts of Scandinavia and
Australia could provide insights that New Zealand can
emulate as it looks to improve survival rates associated
with the disease and launches the new national
network.[5]
Advertisement – scroll to continue reading
In 2014 Norway’s ovarian cancer survival
rate was the highest of six countries in the International
Cancer Benchmarking Partnership (ICBP), which includes
Australia, Canada, Denmark, Ireland, New Zealand, Norway and
the UK, a collaboration of clinicians, policymakers,
researchers and data experts, seeking to explain survival
differences between high-income countries with comprehensive
cancer registries, similar health system expenditure, and
universal health care.[6][7]
Data shows Norway, which
is similar in population size to NZ, increased its five-year
survival rates for ovarian cancer from 34.1% to 46.1% in the
almost two decades from 1995. In contrast, New Zealand’s
five-year survival rates remained relatively static – moving
from 34.6% to 36.3% over the same period.[8],
[9],[10]
Figures from the Cancer Registry of Norway
published in 2023 show their ovarian cancer survival rates
have since increased to 50.3%.[11]
Crosby says while
the available data does not take into account any
improvements made to New Zealand’s healthcare model
following its publication, the current redesign of our
national approach to cancer care by government health
agencies is an opportunity to adopt current global best
practices in this space.
She says early diagnosis is
key to improving outcomes and is calling for the development
of more culturally relevant and targeted resources to
support disease awareness levels of Māori wahine and
Pacific women who are generally at higher risk of ovarian
cancer, compared to those of the European/other ethnic
groups.* [12]
According to data from Te Aho o Te Kahu,
ovarian cancer is the sixth most common cause of cancer
death for New Zealand women. Every 32 hours approximately
one Kiwi woman is diagnosed with ovarian cancer and around
every 60 hours one dies from the disease during this
time.[13],[14], [15]
Data from the WHO shows the
incidence of the disease in New Zealand is projected to grow
19% by 2035.[16]
Researchers found Scandinavian
countries such as Denmark and Norway, which have higher
survival rates for ovarian cancer, utilise national
databases to track treatment patterns and inform quality
improvement initiatives. This approach allows for the
identification of treatment variations, leading to better
patient outcomes. In contrast, New Zealand currently lacks a
comprehensive national auditing system for ovarian cancer
treatment, however, Te Aho o Te Kahu is building the
technology to securely share the relevant data from hospital
information systems to a new national chemotherapy
database.[17][18]
Until 2019, New Zealand was the only
ICBP country without access to a class of medicines known as
PARP inhibitors that help prevent cancer cells from
repairing their DNA, causing the cells to
die.[19][20][21]
Following the funding of the
country’s first PARP inhibitor in 2020, another PARP
inhibitor known as Zejula (niraparib) was funded in 2024
with over 100 people living with advanced ovarian cancer
estimated to benefit from the maintenance treatment,
regardless of whether or not they have a BRCA mutation. New
Zealand now has two Government funded PARP inhibitors –
which is now more closely aligned with other countries in
the benchmarking
partnership.[22][23][24],[25],[26]
Crosby says while
variations in our healthcare systems may mean New Zealand
faces more inherent barriers when compared to countries like
Norway, it is crucial that we work towards continuing to
improve outcomes for Kiwi women with ovarian
cancer.
“Building trust is crucial when working with
Māori and Pacific communities, who are disproportionately
affected by ovarian cancer. However more needs to be done to
focus on fostering partnerships with Māori and Pacific
organisations, building those relationships, and ensuring
that life-saving information is delivered in a way that
resonates with their cultural values and
needs.[27]
“In many cases, ovarian cancer can be
asymptomatic until it advances to the later stages. Some
ovarian cancer subtypes may be faster growing, causing
symptoms such as significant bloating or abdominal pain to
present earlier, however, every individual case is
different, a large proportion of women are diagnosed when
ovarian cancer is advanced,” she
says.[28][29]
Crosby says symptoms of the disease may
include persistent bloating, feeling full quicker,
discomfort, pressure, or pain in the abdomen or pelvic area,
change in bowel habits, fatigue, back pain, needing to
urinate often or urgently, abnormal vaginal bleeding,
indigestion, nausea, or unexplained weight
changes.[30][31][32]
She says community and charitable
organisations need to work together to help decrease the
stigma surrounding the issue of gynaecological health and
ovarian cancer.
“I’d like to see organisations
having ovarian cancer information at their workplaces, on
notice boards, in bathrooms, wherever women can see it and
familiarise themselves with the symptoms.
“This kind
of community awareness where women see it at multiple touch
points could have a trickle-down effect where they receive
the information and pass it on to friends and whanau
also.
“In Australia, which had the second highest
five-year survival rates of ICBP countries, we’ve also
seen large corporates and fashion brands being involved in
ovarian cancer awareness, these brands often have large
social media followings and it would be great to see some
New Zealand companies jump on board and make a similar
commitment,” she says.[33]
Brett Marett, GSK medical
director, says with the burden of ovarian cancer expected to
increase within New Zealand and globally, the development of
treatment options and raised awareness of the disease is
critical.[34],[35]
He says PARP inhibitors are a
targeted maintenance therapy that may increase the length of
time before cancer progresses.[36],[37],[38],
[39][40]
“The access to funded PARP inhibitor
treatment options for ovarian cancer may offer hope for the
many Kiwi women and their whanau that are impacted by this
disease each year,” he says.[41][42]
[1] Cancer
National Clinical Network – Health New Zealand | Te whatu
ora. (n.d.). https://www.tewhatuora.govt.nz/corporate-information/our-health-system/strategic-initiatives-in-health-research-and-innovation/national-clinical-networks/cancer-national-clinical-network.
Accessed 1 Dec 2024.
[2] Cancer National Clinical
Network – Health New Zealand | Te whatu ora. (n.d.). https://www.tewhatuora.govt.nz/corporate-information/our-health-system/strategic-initiatives-in-health-research-and-innovation/national-clinical-networks/cancer-national-clinical-network.
Accessed 1 Dec 2024.
[3] Apply to be a member of the
Cancer National Clinical Network | Pinnacle Practices.
(n.d.). https://www.pinnaclepractices.co.nz/pin-points/apply-to-be-a-member-of-the-cancer-national-clinical-network/.
Accessed 1 Dec 2024.
[4] Cancer National Clinical
Network – Health New Zealand | Te whatu ora. (n.d.). https://www.tewhatuora.govt.nz/corporate-information/our-health-system/strategic-initiatives-in-health-research-and-innovation/national-clinical-networks/cancer-national-clinical-network.
Accessed 1 Dec 2024.
[5] SURVMARK-2 – viz1. (n.d.). https://gco.iarc.fr/survival/survmark/visualizations/viz1/?groupby=%22country%22&period=%225%22&cancer_site=%22Ovary%22&country=%22Australia%22&year=%222014%22&gender=%22Females%22&sorting=%220%22&countries=%5B%22Australia%22%2C%22Canada%22%2C%22Denmark%22%2C%22Ireland%22%2C%22New+Zealand%22%2C%22Norway%22%2C%22United+Kingdom%22%5D.
Accessed 1 Dec 2024.
[6] SURVMARK-2 – viz1. (n.d.). https://gco.iarc.fr/survival/survmark/visualizations/viz1/?groupby=%22country%22&period=%225%22&cancer_site=%22Ovary%22&country=%22Australia%22&year=%222014%22&gender=%22Females%22&sorting=%220%22&countries=%5B%22Australia%22%2C%22Canada%22%2C%22Denmark%22%2C%22Ireland%22%2C%22New+Zealand%22%2C%22Norway%22%2C%22United+Kingdom%22%5D.
Accessed 1 Dec 2024. Five year net survival data in 2014
only available for Australia, Canada, Denmark, New Zealand,
Norway, and the UK. Ireland was part of the ICBP but data
was not available for this year.
[7] McPhail, S.,
Barclay, M. E., Johnson, S. A., Swann, R., Alvi, R.,
Barisic, A., Bucher, O., Creighton, N., Denny, C. A., Dewar,
R. A., Donnelly, D. W., Dowden, J. J., Downie, L., Finn, N.,
Gavin, A. T., Habbous, S., Huws, D. W., May, L., McClure, C.
A., . . . Zalcberg, J. R. (2024). Use of chemotherapy in
patients with oesophageal, stomach, colon, rectal, liver,
pancreatic, lung, and ovarian cancer: an International
Cancer Benchmarking Partnership (ICBP) population-based
study. The Lancet Oncology, 25(3), 338–351. https://doi.org/10.1016/s1470-2045(24)00031-7
Accessed 1 Dec 2024.
[8]Country comparison: Norway
/ New Zealand. (n.d.). Worlddata.info.
https://www.worlddata.info/country-comparison.php?country1=NOR&country2=NZL.
Accessed 1 Dec 2024.
[9] SURVMARK-2 – viz1. (n.d.). https://gco.iarc.fr/survival/survmark/visualizations/viz1/?groupby=%22country%22&period=%225%22&cancer_site=%22Ovary%22&country=%22Australia%22&year=%221995%22&gender=%22Females%22&sorting=%220%22&countries=%5B%22Australia%22%2C%22Canada%22%2C%22Denmark%22%2C%22Ireland%22%2C%22New+Zealand%22%2C%22Norway%22%2C%22United+Kingdom%22%5D.
Accessed 1 Dec 2024.
[10] SURVMARK-2 – viz1. (n.d.).
https://gco.iarc.fr/survival/survmark/visualizations/viz1/?groupby=%22country%22&period=%225%22&cancer_site=%22Ovary%22&country=%22Australia%22&year=%222014%22&gender=%22Females%22&sorting=%220%22&countries=%5B%22Australia%22%2C%22Canada%22%2C%22Denmark%22%2C%22Ireland%22%2C%22New+Zealand%22%2C%22Norway%22%2C%22United+Kingdom%22%5D.
Accessed 1 Dec 2024.
[11] Giske Ursin;National quality
registry for gynecological cancer;2023;1-112.
[12]
Ovarian cancer – early detection and referral – bpacnz.
(n.d.). https://bpac.org.nz/2023/ovarian-cancer.aspx
Accessed 1 Dec 2024.
*In 2019, the age-standardised
incidence rate for Pacific peoples was 19.5 per 100,000
females which was 2.0 times greater than the rate in Maori
(9.6 per 100,000 females) and 2.2 times greater than in
European/Other ethnic groups (8.9 per 100,000 females). Data
not based on studies powered for statistical comparison
across ethnicities.
[13] Te Aho o Te Kahu – Cancer
Control Agency. (n.d.). Te Aho O Te Kahu – Cancer Control
Agency. https://teaho.govt.nz/cancer-numbers/cancer-deaths.
(Screenshot here).
Accessed 1 Dec 2024.
[14] Te Whata Ora. Cancer web
tool. (n.d.-b). https://tewhatuora.shinyapps.io/cancer-web-tool/
Rate of All Ovarian (C56) Cancer Registrations in 2018-2022
by Prioritised Ethnicity. Accessed 13 Dec 2024.
[15]
Te Whata Ora. Cancer web tool. (n.d.-b). Deaths. https://tewhatuora.shinyapps.io/cancer-web-tool/
Rate of All Ovarian (C56) Cancer Deaths in 2018-2022 by
Prioritised Ethnicity. Accessed 13 Dec 2024.
[16] WHO
– Cancer tomorrow. (n.d.). https://gco.iarc.fr/tomorrow/en/dataviz/trends?types=0_1&sexes=2&mode=population&group_populations=1&multiple_populations=1&multiple_cancers=0&cancers=25&populations=554
(Calculations = NZ incidence from 410 to 486 = 19% increase
from 2025 to 2035). Accessed 19 Dec 2024.
[17] Norell,
C. H., Butler, J., Farrell, R., Altman, A., Bentley, J.,
Cabasag, C. J., Cohen, P. A., Fegan, S., Fung-Kee-Fung, M.,
Gourley, C., Hacker, N. F., Hanna, L., Høgdall, C. K.,
Kristensen, G., Kwon, J., McNally, O., Nelson, G., Nordin,
A., O’Donnell, D., . . . Harrison, S. (2020). Exploring
international differences in ovarian cancer treatment: a
comparison of clinical practice guidelines and patterns of
care. International Journal of Gynecological Cancer,
30(11), 1748–1756. https://doi.org/10.1136/ijgc-2020-001403
Accessed 1 Dec 2024.
[18] Te Aho o Te Kahu – Cancer
Control Agency. (n.d.). Te Aho O Te Kahu – Cancer Control
Agency. https://teaho.govt.nz/reports/canshare/act-now-programme.
Accessed 20 Dec 2024.
[19] Norell, C. H., Butler, J.,
Farrell, R., Altman, A., Bentley, J., Cabasag, C. J., Cohen,
P. A., Fegan, S., Fung-Kee-Fung, M., Gourley, C., Hacker, N.
F., Hanna, L., Høgdall, C. K., Kristensen, G., Kwon, J.,
McNally, O., Nelson, G., Nordin, A., O’Donnell, D., . . .
Harrison, S. (2020). Exploring international differences in
ovarian cancer treatment: a comparison of clinical practice
guidelines and patterns of care. International Journal of
Gynecological Cancer, 30(11), 1748–1756. https://doi.org/10.1136/ijgc-2020-001403.
Accessed 20 Dec 2024
[20] Definition of PARP inhibitor
– NCI Dictionary of Cancer Terms. (n.d.). Cancer.gov.
Accessed 1 Dec 2024. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/parp-inhibitor.
Accessed 20 Dec 2024
[21] PARP inhibitors as initial
treatment for ovarian cancer. (2019, October 29). National
Cancer Institute. https://www.cancer.gov/news-events/cancer-currents-blog/2019/parp-inhibitors-ovarian-cancer-initial-treatment#:~:text=PARP%20Inhibitors%20Show%20Promise%20as%20Initial%20Treatment%20for%20Ovarian%20Cancer,-Subscribe&text=PARP%20inhibitors%20block%20the%20repair%20of%20broken%20DNA.
Accessed 1 Dec 2024.
[22] PHARMAC;2019;1-7;Proposal to
fund two new cancer treatments: olaparib and
fulvestrant
[23] Medsafe.govt.nz
Zejula (niraparib) https://www.medsafe.govt.nz/profs/datasheet/z/zejulacap.pdf
(Accessed 28 Jan 2025)
[24] González Martín A, et
al. N Engl J Med 2019;381:2391–402. Accessible here.
(Accessed 1 Dec 2024)
[25] Pharmac;2024;1-2;Summary of
decision: niraparib for ovarian cancer; available at https://pharmac.govt.nz/news-and-resources/news/summary-of-decision-niraparib-for-ovarian-cancer
(Accessed 1 Dec 2024)
[26] Norell CH;Int J Gynecol
Cancer;2020;30;1748–1756
[27] Ovarian cancer –
early detection and referral – bpacnz. (n.d.). https://bpac.org.nz/2023/ovarian-cancer.aspx
Accessed 1 Dec 2024.
[28] Ovarian cancer – early
detection and referral – bpacnz. (n.d.). https://bpac.org.nz/2023/ovarian-cancer.aspx
Accessed 1 Dec 2024.
[29] Doubeni, C. A., Doubeni, A.
R. B., & Myers, A. E. (2016, June 1). Diagnosis and
management of ovarian cancer. AAFP. https://www.aafp.org/pubs/afp/issues/2016/0601/p937.html.
Accessed 1 Dec 2024.
[30] Doubeni, C. A., Doubeni, A.
R. B., & Myers, A. E. (2016, June 1). Diagnosis and
management of ovarian cancer. AAFP. https://www.aafp.org/pubs/afp/issues/2016/0601/p937.html.
Accessed 1 Dec 2024.
[31] Ovarian cancer – Cancer
Society NZ. (2021, January 12). Cancer Society NZ. https://www.cancer.org.nz/cancer/types-of-cancer/ovarian-cancer/#:~:text=Signs%20and%20symptoms%20of%20ovarian%20cancer%20may%20include%3A,vaginal%20bleeding%208%20weight%20changes%20for%20no%20reason.
Accessed 1 Dec 2024.
[32] Signs and symptoms of
ovarian cancer & cysts, masses, tumors. (n.d.). City of
Hope. https://www.cancercenter.com/cancer-types/ovarian-cancer/symptoms
. Accessed 29 Jan 2025.
[33] SURVMARK-2 – viz1.
(n.d.). https://gco.iarc.fr/survival/survmark/visualizations/viz1/?groupby=%22country%22&period=%225%22&cancer_site=%22Ovary%22&country=%22Australia%22&year=%222014%22&gender=%22Females%22&sorting=%220%22&countries=%5B%22Australia%22%2C%22Canada%22%2C%22Denmark%22%2C%22Ireland%22%2C%22New+Zealand%22%2C%22Norway%22%2C%22United+Kingdom%22%5D.
Accessed 1 Dec 2024. Five year net survival data in 2014
only available for Australia, Canada, Denmark, New Zealand,
Norway, and the UK
[34] WHO – Cancer tomorrow. (n.d.).
https://gco.iarc.fr/tomorrow/en/dataviz/trends?types=0_1&sexes=2&mode=population&group_populations=1&multiple_populations=1&multiple_cancers=0&cancers=25&populations=554.
Accessed 1 Dec 2024.
[35] Everhobbes. (n.d.). Ovarian
Cancer key Stats*. World Ovarian Cancer Coalition. https://worldovariancancercoalition.org/about-ovarian-cancer/key-stats/#:~:text=According%20to%20Globocan’s%202022%20projections,of%20almost%2070%25%20from%202022.
Accessed 1 Dec 2024.
[36] Hunia J, Gawalski K,
Szredzka A, Suskiewicz MJ, Nowis D. The potential of PARP
inhibitors in targeted cancer therapy and immunotherapy.
Front Mol Biosci. 2022 Dec 1;9:1073797. doi:
10.3389/fmolb.2022.1073797. PMID: 36533080; PMCID:
PMC9751342.
[37] PARP inhibitors as initial treatment
for ovarian cancer. (2019, October 29). National Cancer
Institute. https://www.cancer.gov/news-events/cancer-currents-blog/2019/parp-inhibitors-ovarian-cancer-initial-treatment#:~:text=PARP%20Inhibitors%20Show%20Promise%20as%20Initial%20Treatment%20for%20Ovarian%20Cancer,-Subscribe&text=PARP%20inhibitors%20block%20the%20repair%20of%20broken%20DNA.
Accessed 1 Dec 2024.
[38] González Martín A, et al.
N Engl J Med 2019;381:2391–402. Accessible here.
(Accessed 1 Dec 2024)
[39] Li, N., Zhu, J., Yin, R.,
Wang, J., Pan, L., Kong, B., Zheng, H., Liu, J., Wu, X.,
Wang, L., Huang, Y., Wang, K., Zou, D., Zhao, H., Wang, C.,
Li, W., An, L., Lou, G., Li, G., Wu, L. (2022). Efficacy and
safety of niraparib as maintenance treatment in patients
with newly diagnosed advanced ovarian cancer using an
individualized starting dose (PRIME Study): A randomized,
double-blind, placebo-controlled, phase 3 trial (LBA 5).
Gynaecologic Oncology, 166, S50–S51. https://doi.org/10.1016/s0090-8258(22)01298-7.
Accessed 1 Dec 2024.
[40] Baradács I, Teutsch B,
Váradi A, Bilá A, Vincze Á, Hegyi P, Fazekas T,
Komoróczy B, Nyirády P, Ács N, Bánhidy F, Lintner B.
PARP inhibitor era in ovarian cancer treatment: a systematic
review and meta-analysis of randomized controlled trials. J
Ovarian Res. 2024 Feb 26;17(1):53. doi:
10.1186/s13048-024-01362-y. PMID: 38409030; PMCID:
PMC10895809.
[41] Zejula CMI https://www.medsafe.govt.nz/Consumers/cmi/z/zejula.pdf
Accessed 20 Dec 2024
[42] Pharmac;2024;1-2;Summary of
decision: niraparib for ovarian cancer; available at https://pharmac.govt.nz/news-and-resources/news/summary-of-decision-niraparib-for-ovarian-cancer
(Accessed 1 Dec 2024)
[43] Zejula CMI https://www.medsafe.govt.nz/Consumers/cmi/z/zejula.pdf
(Accessed 1 Dec 2024)
[44] GlaxoSmithKline New
Zealand. ZEJULA Data Sheet. GSK NZ; 2023 https://www.medsafe.govt.nz/profs/Datasheet/z/zejulacap.pdf
Accessed 1 Dec 2024.
Safety Information
[43]
Please talk to your doctor if you have any
questions about your specific situation. The following side
effects may occur when taking Zejula; tiredness, weakness,
feeling sick, stomach pain, vomiting, constipation,
diarrhoea, indigestion, decreased appetite, inability to
sleep, headache, dizziness, changes in taste of food, runny
or stuffy nose, shortness of breath, cough, high blood
pressure, urinary tract infection, heart palpitations, back
pain and joint pain.
About Zejula
Zejula is
indicated: [44]
- for the maintenance treatment of
adult patients with advanced epithelial ovarian, fallopian
tube or primary peritoneal cancer who are in a complete or
partial response to first-line platinum-based
chemotherapy. - for the maintenance treatment of adult
patients with recurrent epithelial ovarian, fallopian tube,
or primary peritoneal cancer who are in complete or partial
response to platinum-based
chemotherapy.
© Scoop Media



















Discussion about this post